DVT

Clarius and ThinkSono Introduce a New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs

Retrieved on: 
금요일, 4월 5, 2024
Cloud, CE marking, Diagnosis, Deep vein thrombosis, Algorithm, Partnership, Research, Class, AI, Patient, Leg, DVT, Temple Health, SDK, Marketing, Nursing, FDA, Clarius, Medical device

VANCOUVER, BC, April 5, 2024 /PRNewswire/ -- Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.

Key Points: 
  • ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval.
  • ThinkSono Guidance enables non-ultrasound trained healthcare professionals to use the Clarius handheld ultrasound scanner to collect DVT exam data for a qualified clinician to review.
  • ThinkSono now uses Clarius' Solum software development kit (SDK), enabling the company to create a bespoke solution tailored to their DVT application.
  • The Clarius SDK suite empowers third party developers to seamlessly integrate AI-powered ultrasound software with Clarius handheld ultrasound systems, the Clarius App, and the Clarius Cloud exam management platform.

Restaking Platform PrimeStaked Reopens Deposits Following $40M in Demand

Retrieved on: 
화요일, 3월 12, 2024
Ethereum, TVL, Realme, DVT, ETH, Decentralized finance, AUM, Methamphetamine, OETH, Cryptocurrency

Origin Protocol , a leading DeFi platform, has announced the remarkable success of a newly launched liquid restaking platform, PrimeStaked , which has achieved a Total Value Locked (TVL) milestone of over $40 million and has just reopened deposits with added support for ETH restaking.

Key Points: 
  • Origin Protocol , a leading DeFi platform, has announced the remarkable success of a newly launched liquid restaking platform, PrimeStaked , which has achieved a Total Value Locked (TVL) milestone of over $40 million and has just reopened deposits with added support for ETH restaking.
  • Built on top of EigenLayer, the platform has attracted $35+ million in OETH deposits on PrimeStaked and $80 million of total OETH deposits on EigenLayer.
  • On March 11, PrimeStaked opened support for native ETH restaking, which will accept deposits on an ongoing basis.
  • PrimeStaked has partnered with P2P.org, a staking provider with $1B+ in AUM, and ssv.network, a distributed validator technology (DVT), to support ETH deposits for liquid restaking.

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Retrieved on: 
화요일, 3월 12, 2024
Deep vein thrombosis, Pulmonary embolism, VTE, Incidence, Sequela, CAVA, Patient, Post-thrombotic syndrome, Research, PTS, DVT, Randomized controlled trial, Safety, FACS, American Venous Forum, Data, Pharmaceutical industry

IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

Key Points: 
  • IRVINE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.
  • The interim results are the largest prospective, multi-center two-year dataset in deep vein thrombosis (DVT) since the ATTRACT trial and confirm the excellent safety, effectiveness, and long-term outcomes of the ClotTriever system in real-world DVT patients.
  • Patients had low incidence of independently adjudicated safety events related to rethrombosis, with only 5.0% and 8.4% at 30-days and 6 months, respectively.
  • We remain committed to establishing the ClotTriever and FlowTriever systems as standard of care for deep vein thrombosis and pulmonary embolism (PE) patients.”

Sky Harbour Group Corporation Announces its 2023 Financial Results; Updates on New Ground Leases, Construction and Hangar Leasing; Injects Equity into Obligated Group and Files Various Registration Statements with SEC

Retrieved on: 
수요일, 3월 27, 2024
Air, Transport, Transportation, Commercial Building & Real Estate, Construction & Property, Travel, SGR, MSRB, Orlando Executive Airport, SH34, Form, Webcast, City, Tenant, Aviation, Acquisition, MetroCentre, ADS, Form S-3, DVT, Silicon, GDP, PIPE, BNA, SJC, Obligation, Airport, APA, Economics, San Jose International Airport, OPF

New ground lease at SJC, encompassing an existing hangar facility to be made operational over the coming several weeks, and land for additional future development.

Key Points: 
  • New ground lease at SJC, encompassing an existing hangar facility to be made operational over the coming several weeks, and land for additional future development.
  • New ground lease at ORL, with expected construction commencement in Q2 2025.
  • Construction of Phases 1 in Denver, Phoenix, and Dallas delayed by 3-4 months, with an estimated $26 - $28 million non-recurring remediation cost.
  • We are now gearing up to perform at scale.”
    Sky Harbour will host a live conference call and concurrent webcast at 5 p.m.

Inovia Vein Calls for Increased Awareness Around Deep Vein Thrombosis Risks During DVT Awareness Month

Retrieved on: 
화요일, 3월 5, 2024
Health, Consumer, Women, Surgery, Seniors, Other Health, Men, Pulmonary embolism, Pacific Northwest, Education, Tenderness, Obesity, Pain, Deep vein thrombosis, Swelling, Leg, DVT, Pregnancy, Vein, Risk, Patient, Bed rest, Trauma, Cancer, Birth control

With March being nationally recognized as Deep Vein Thrombosis (DVT) Awareness Month , Inovia Vein , a leading provider of world-class vein health services, is calling for enhanced education and awareness about this potentially life-threatening condition.

Key Points: 
  • With March being nationally recognized as Deep Vein Thrombosis (DVT) Awareness Month , Inovia Vein , a leading provider of world-class vein health services, is calling for enhanced education and awareness about this potentially life-threatening condition.
  • Inovia Vein’s vein health experts are stepping up to spread the word about the condition.
  • “That said, at Inovia Vein, we believe every month should be ‘DVT Awareness Month,’ and we are dedicated to educating the communities we serve and beyond about prevention and education.
  • Inovia Vein, the leading provider of vein health services, is dedicated to offering comprehensive and compassionate care to patients with venous disorders.

Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis

Retrieved on: 
화요일, 2월 20, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Safety, Deep vein thrombosis, Bayer, DVT, Patient, SIRIUS, Executive Committee, Pharmaceutical industry

Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).

Key Points: 
  • Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).
  • The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high medical relevance.
  • "We are excited to advance our anti-α2ap antibody to the next stage of clinical development in patients with deep vein thrombosis,” said Christian Rommel, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development.
  • Following the successful first-in-human trial, the goal of the randomized, double-blind, placebo-controlled, multi-center Phase II study (SIRIUS study) is to assess the efficacy and safety of BAY3018250 in patients with symptomatic proximal deep vein thrombosis.

Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update

Retrieved on: 
수요일, 2월 14, 2024
Investigational New Drug, Peripheral edema, Anemia, Gastroenteritis, Medicine, Periodic breathing, Leukopenia, Diarrhea, Quality of life, Cough, Dizziness, Deep vein thrombosis, Nausea, Vomiting, DVT, Common, Tremor, Back pain, Constipation, Safety, Dexamethasone, First grade, Lower respiratory tract infection, URTI, Bronchitis, Therapy, Fatigue, Bortezomib, Pharmacokinetics, Thrombocytopenia, Rash, Patient, Neutropenia, Acceleration, Multiple myeloma, RMOC, IND, Insomnia, Lenalidomide, Appetite, Abdominal pain, Weakness, Pharmaceutical industry

The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).

Key Points: 
  • The ongoing study evaluates the safety, pharmacokinetics, and efficacy of continuous subcutaneous administration of low-dose lenalidomide (STAR-LLD) in conjunction with dexamethasone and bortezomib (Velcade®).
  • Remarkably, the trial is progressing ahead of schedule and with the addition of RMOC is now projected to conclude enrollment by Q1/2024.
  • I’m excited about the potential opportunity STAR-LLD can bring to multiple myeloma patients.”
    Earlier last month, Starton disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.
  • Notably, no hematologic toxicities greater than Grade 1 have been observed following up to 3 cycles of treatment thus far.

Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
수요일, 1월 3, 2024
Quality of life, Leukopenia, URTI, Constipation, Lower respiratory tract infection, IND, Insomnia, CD8, Diarrhea, PD-1, DVT, Anemia, Gastroenteritis, Tremor, Fatigue, Common, CD4, Nausea, Multiple myeloma, Neutropenia, Abdominal pain, Therapy, Lenalidomide, Pharmacokinetics, Weakness, Dizziness, Thrombocytopenia, Cytotoxic T cell, Dexamethasone, Appetite, Periodic breathing, Bortezomib, Toxicity, Back pain, Patient, Safety, Peripheral edema, Deep vein thrombosis, Vomiting, Cough, Rash, Bronchitis

Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date. Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks. In comparison, adverse events in these patients observed during a prior regimen containing Revlimid® included nausea, vomiting, deep vein thrombosis (DVT), upper respiratory tract infections (URTI), anemia, and fatigue. None of the more common side effects of lenalidomide (Revlimid®), which include diarrhea, fatigue, anemia, constipation, neutropenia, leukopenia, peripheral edema, insomnia, muscle cramp/spasms, abdominal pain, back pain, nausea, asthenia, pyrexia, bronchitis, nasopharyngitis, gastroenteritis, cough, rash, dyspnea, dizziness, decreased appetite, thrombocytopenia, and tremor, have been observed with STAR-LLD. Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects. These data suggest that STAR-LLD may prove to be superior in tolerability to oral Revlimid, expanding the number of patients that get the full Revlimid® benefit and improving quality of life.

Key Points: 
  • Patient acceptance of self-administration using the ambulatory pump for lenalidomide delivery has been confirmed in this study.
  • Remarkably, there were no hematologic toxicities greater than Grade 1 observed to date.
  • Only a single drug-related adverse event was reported -- subcutaneous induration at the injection site which resolved within two weeks.
  • Up to 30% of patients discontinue use of Revlimid® and roughly 70% dose reduce as a result of these adverse effects.

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Medical Subject Headings, Marketing, Liver, Coronary thrombosis, INN, Risk, Pulmonary embolism, STEMI, ATC, DVT, Unstable angina, Bleeding, International, ASA, Myocardial infarction, Antithrombin, Language, Heart, Stroke, European Medicines Agency, Infection, Extracorporeal, Sodium oxide, Rheumatology, Select, Chest pain, Patient, Aspirin, Vein, Safety, Anatomy, Medicine, Leg, Deep vein thrombosis, IIA, Sodium, Skin, Birth control

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
화요일, 1월 2, 2024
Marketing, Artery, Heart, INN, Risk, Hypertension, Population, Embolism, Rivaroxaban, Moyamoya disease, Death, Thrombus, Coronary artery disease, Chest pain, Vein, Facial muscles, Anatomy, ACS, IIA, Knee, ATC, Clopidogrel, DVT, Bleeding, Disease, Ageing, Atrial fibrillation, ASA, Safety, Leg, Medical Subject Headings, Hip, Peripheral artery disease, Pulmonary embolism, Thrombin, Diabetes, International, CAD, Language, Ventricular fibrillation, Tablet, Select, Aspirin, Patient, Acute coronary syndrome, Coronary thrombosis, Blood, Brain, VTE, Recurrence, European Medicines Agency, Ticlopidine, Deep vein thrombosis, PAD, Generic drug

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 5, Status: Authorised